Clinical trial

The Adjuvant Effect of HPV Vaccination on Recurrence of Cervical Intraepithelial Neoplasia Grade 2 or Worse in Women Undergoing Conization: Retrospective Cohort Study

Name

PAVIVE2024

Description

Assessment of the association between human papillomavirus vaccination (HPV) and recurrences of cervical intraepithelial neoplasia grade 2 or worse (CIN2+) in women undergoing conization.

Trial arms

Trial start

2024-05-01

Estimated PCD

2024-12-31

Trial end

2025-07-01

Status

Not yet recruiting

Treatment

vaccination against human papillomavirus infection (HPV vaccination)

Women with or without HPV vaccination before or after excision

Arms:

single cohort of women with cervical excision for CIN2+

Size

1000

Primary endpoint

CIN2+ recurrence rate

2010-2024

Eligibility criteria

Inclusion Criteria: * Women \>18 years, with conization for CIN2+ (HSIL) * Women who had more than one examination during a follow-up period of \>6 months. Exclusion Criteria: - Women who underwent hysterectomy after conization. * Women who had excision procedures other than cervical excision. * Women who did not undergo any other cytological/histological examinations. * Women with more than one conization before CIN2+ recurrence

Protocol

{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'RETROSPECTIVE'}, 'enrollmentInfo': {'count': 1000, 'type': 'ESTIMATED'}}

Updated at

2024-02-15

1 organization

1 product

2 indications

Organization

Charles University

Product

HPV vaccination

Indication

Cervical Intraepithelial Neoplasia Grade 2/3

Indication

Recurrence